PressAugust 29, 2022 Wellbeing Subsidiary KGK Science Announces AKL No Objection Status for ProGo Branded Ingredient from FDA
VideoAugust 29, 2022 Core One Labs Engages in Talks With GMP Manufacturing Partner for Commercial Scale Production of Proprietary Biosynthetic Psilocybin
PressAugust 26, 2022 B.More Receives FDA Investigational New Drug Approval for Psilocybin Alcohol Use Disorder Program Phase 2b Clinical Trial
PressAugust 26, 2022 PharmaDrug Advances Psychedelics Pharmaceutical Program Focused on DMT and DMT Analogues
PressAugust 26, 2022 Awakn Life Sciences Signs Agreement with a Leading Drug Development Company to Deepen IP Moat for Its Lead Program
PressAugust 26, 2022 SciSparc Ltd. Announces Additional Positive Results for the Cocaine Addiction Treatment of its Psychedelic-based Pharma Collaboration with Clearmind Medicine Inc.
PressAugust 26, 2022 PSYC’s Bonfire Platform Development Progresses; Will Host Free Virtual Community Event on August 29th
PressAugust 26, 2022 Cybin: Clinilabs Granted Schedule I DEA License for CYB003 Phase 1/2a First-In-Human Clinical Trial – Form 6-K
PressAugust 25, 2022 BetterLife Lead Drug (BETR-001) Promotes Structural Neural Plasticity with Possible Nootropic Effects Similar to That of LSD Without Hallucinogenic Side Effects
PressAugust 25, 2022 MindMed Announces First Patient Dosed in Phase 2b Trial of MM-120 in Generalized Anxiety Disorder
PressAugust 25, 2022 Optimi Health Announces Canadian Retail and E-Commerce Distribution Agreements for Functional Mushroom Supplements and Appoints Chief Financial Officer to its Board of Directors
PressAugust 24, 2022 Freedom Biosciences Emerges from Stealth with $10.5 Million Seed Financing to Develop Next-Generation Ketamine and Psychedelic-based Mental Health Treatments
PressAugust 24, 2022 Innovation1 Biotech Announces Filing of Patent Application for Novel Combination Therapy Targeting Addiction
PressAugust 24, 2022 NRx Pharmaceuticals Provides Business Update and Reports Second Quarter 2022 Results Focusing on Reactivation & Advancement of its Psychiatry Franchise
PressAugust 24, 2022 GH Research Reports Second Quarter 2022 Financial Results and Provides Business Updates
